ITRM Iterum Therapeutics plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ITRM

Price (delayed)

$1.52

Market cap

$24.97M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.96

Enterprise value

$37.82M

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people ...

Highlights
The debt fell by 33% YoY and by 3.3% QoQ
The net income fell by 23% QoQ but it rose by 14% YoY
ITRM's EPS is down by 21% QoQ but it is up by 18% YoY
Iterum Therapeutics's equity has shrunk by 123% YoY
ITRM's quick ratio has dropped by 74% year-on-year and by 19% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.iterumtx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of ITRM
Market
Shares outstanding
16.43M
Market cap
$24.97M
Enterprise value
$37.82M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$36.33M
EBITDA
-$34.58M
Free cash flow
-$39.34M
Per share
EPS
-$2.96
Free cash flow per share
-$3.04
Book value per share
-$0.49
Revenue per share
$0
TBVPS
$2.03
Balance sheet
Total assets
$26.26M
Total liabilities
$32.66M
Debt
$18.96M
Equity
-$6.4M
Working capital
$12.08M
Liquidity
Debt to equity
-2.96
Current ratio
1.89
Quick ratio
1.77
Net debt/EBITDA
-0.37
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-87.6%
Return on equity
-664%
Return on invested capital
-79.4%
Return on capital employed
-285.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ITRM stock price

How has the Iterum Therapeutics stock price performed over time
Intraday
-3.18%
1 week
-10.06%
1 month
-1.94%
1 year
34.51%
YTD
-22.84%
QTD
-1.3%

Financial performance

How have Iterum Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$47.47M
Net income
-$38.37M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 56% year-on-year and by 8% since the previous quarter
The net income fell by 23% QoQ but it rose by 14% YoY

Growth

What is Iterum Therapeutics's growth rate over time

Valuation

What is Iterum Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ITRM's EPS is down by 21% QoQ but it is up by 18% YoY
Iterum Therapeutics's equity has shrunk by 123% YoY

Efficiency

How efficient is Iterum Therapeutics business performance
ITRM's ROA has shrunk by 52% QoQ and by 47% YoY
The ROIC has declined by 48% since the previous quarter and by 32% year-on-year

Dividends

What is ITRM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ITRM.

Financial health

How did Iterum Therapeutics financials performed over time
The total assets is 20% smaller than the total liabilities
ITRM's quick ratio has dropped by 74% year-on-year and by 19% since the previous quarter
ITRM's current ratio has dropped by 73% year-on-year and by 20% since the previous quarter
The debt to equity has plunged by 152% from the previous quarter
Iterum Therapeutics's equity has shrunk by 123% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.